Dakota Wealth Management Purchases 5,595 Shares of Astrazeneca Plc $AZN

Dakota Wealth Management grew its stake in shares of Astrazeneca Plc (NYSE:AZN) by 115.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,449 shares of the company’s stock after buying an additional 5,595 shares during the period. Dakota Wealth Management’s holdings in Astrazeneca were worth $961,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Cibc World Market Inc. increased its holdings in shares of Astrazeneca by 21.5% in the third quarter. Cibc World Market Inc. now owns 64,421 shares of the company’s stock valued at $4,942,000 after purchasing an additional 11,398 shares during the period. TD Asset Management Inc boosted its stake in shares of Astrazeneca by 20.0% during the 3rd quarter. TD Asset Management Inc now owns 1,089,612 shares of the company’s stock worth $83,595,000 after acquiring an additional 181,273 shares in the last quarter. Y Intercept Hong Kong Ltd grew its holdings in Astrazeneca by 111.6% in the third quarter. Y Intercept Hong Kong Ltd now owns 66,643 shares of the company’s stock valued at $5,113,000 after purchasing an additional 35,148 shares during the period. AMG National Trust Bank increased its holdings in Astrazeneca by 20.4% in the 3rd quarter. AMG National Trust Bank now owns 42,983 shares of the company’s stock worth $3,298,000 after acquiring an additional 7,289 shares in the last quarter. Finally, Oxbow Advisors LLC raised its stake in Astrazeneca by 96.2% in the 3rd quarter. Oxbow Advisors LLC now owns 77,594 shares of the company’s stock valued at $5,953,000 after purchasing an additional 38,043 shares during the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently issued reports on AZN. Wall Street Zen upgraded Astrazeneca from a “hold” rating to a “buy” rating in a research report on Friday, March 20th. Morgan Stanley reissued an “overweight” rating and set a $103.00 price objective on shares of Astrazeneca in a research note on Wednesday, December 3rd. HSBC restated a “buy” rating and issued a $108.00 target price on shares of Astrazeneca in a report on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a report on Friday, February 6th. Finally, TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $95.75.

Astrazeneca Stock Up 0.1%

NYSE:AZN opened at $188.57 on Monday. Astrazeneca Plc has a fifty-two week low of $122.48 and a fifty-two week high of $212.71. The company has a debt-to-equity ratio of 0.51, a current ratio of 0.94 and a quick ratio of 0.72. The company has a market cap of $292.45 billion, a P/E ratio of 32.48, a P/E/G ratio of 1.42 and a beta of 0.32.

Astrazeneca Dividend Announcement

The company also recently disclosed a dividend, which was paid on Monday, March 23rd. Investors of record on Friday, February 20th were issued a $1.595 dividend. This represents a dividend yield of 156.0%. The ex-dividend date was Friday, February 20th. Astrazeneca’s payout ratio is currently 66.26%.

Astrazeneca News Summary

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Late‑stage trial win — Tozorakimab met primary goals in two pivotal trials, reducing chronic obstructive pulmonary disease flare‑ups versus placebo; the surprise positive readout is driving optimism about near‑term commercialization potential and pipeline momentum. AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed
• Positive Sentiment: Regulatory and commercial implications — Reuters and other outlets highlight the meaningful reduction in flare‑ups and the significance of a successful phase III outcome for a disease area where competitors have struggled, which increases the drug’s value on AstraZeneca’s roadmap. AstraZeneca drug reduces COPD flare ups in late-stage trials
• Positive Sentiment: Clinical confirmation across endpoints — The Wall Street Journal and other reports emphasize that the trials hit their primary endpoints by lowering symptom worsening rates, reinforcing confidence in the data’s robustness and the potential for label and payer discussions. AstraZeneca Lung Disease Drug Candidate Hits Goals in Late-Stage Trials
• Neutral Sentiment: Stock movement vs. market — Coverage notes AZN advanced while broader markets were down, indicating the move is company‑specific (trial news/pipeline) rather than market driven. Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors
• Neutral Sentiment: Analyst positioning — AstraZeneca has a consensus analyst rating of “Moderate Buy,” which supports the stock’s upside but does not by itself explain today’s move; analyst views may follow as investigators and investors digest full data and commercial assumptions. Astrazeneca Plc (NYSE:AZN) Receives Consensus Rating of “Moderate Buy” from Analysts

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.